How to Get Lantus (Insulin Glargine) in Louisiana

What Is Lantus and Why Is a Prescription Required?

Lantus is a recombinant human insulin analogue that provides a steady, peakless basal insulin effect lasting approximately 24 hours after a single subcutaneous injection [1]. The FDA approved insulin glargine (Lantus) for adults with type 1 and type 2 diabetes and for pediatric patients aged 6 and older [2]. Because insulin is a Schedule-exempt but prescription-only biological product under federal law, a licensed prescriber must evaluate your diagnosis, fasting glucose, HbA1c, kidney function, and current medication list before issuing a valid order.

The 2024 American Diabetes Association (ADA) Standards of Care define basal insulin as the preferred initial injectable agent for type 2 diabetes when oral agents alone are insufficient, stating: "Basal insulin is the simplest insulin regimen and is often prescribed in combination with oral agents" [3]. For type 1 diabetes, basal insulin forms the backbone of every physiologic replacement strategy.

Insulin glargine's pharmacokinetic profile, specifically its slow absorption from a microprecipitate depot at the subcutaneous injection site, produces a relatively flat activity curve with no pronounced peak [1]. That profile reduces nocturnal hypoglycemia risk compared with NPH insulin, a finding confirmed in multiple head-to-head randomized trials [4].

The ORIGIN Trial: Why Clinicians Trust Long-Term Glargine Use

The ORIGIN (Outcome Reduction With Initial Glargine Intervention) trial enrolled 12,537 adults with dysglycemia (impaired fasting glucose, impaired glucose tolerance, or early type 2 diabetes) at cardiovascular risk and randomized them to insulin glargine titrated to a fasting glucose of 95 mg/dL or standard care [5]. Over a median follow-up of 6.2 years, the rate of the primary composite cardiovascular outcome was 2.94 events per 100 person-years in the glargine group versus 2.85 per 100 person-years in the standard-care group (hazard ratio 1.02; 95% CI 0.94, 1.11; P<0.001 for non-inferiority), establishing that long-term glargine use carries no excess cardiovascular risk [5].

Severe hypoglycemia occurred in 1.00 event per 100 person-years with glargine versus 0.31 per 100 person-years with standard care, a difference prescribers use to counsel patients on self-monitoring frequency [5]. ORIGIN remains the longest dedicated cardiovascular outcomes study for any basal insulin and is frequently cited by endocrinologists when justifying long-term Lantus therapy.

Who Can Prescribe Lantus in Louisiana?

Three categories of licensed clinicians may legally issue a Lantus prescription in Louisiana.

Physicians (MD/DO). Any Louisiana-licensed MD or DO with an active DEA registration may prescribe Lantus. Endocrinologists, primary care physicians, and internal medicine specialists are the most common prescribers. The Louisiana State Board of Medical Examiners governs physician licensure and publishes active license data publicly [6].

Nurse Practitioners (NPs). Louisiana grants NPs full practice authority under the Louisiana Board of Nursing. An NP may diagnose, treat, and prescribe Schedule II through V controlled substances and all non-controlled prescription drugs, including insulin, without a physician collaboration agreement [7]. This expansion of NP authority significantly increased the number of diabetes prescribers available in rural parishes.

Physician Assistants (PAs). PAs in Louisiana operate under a supervision agreement with a licensed physician. Within that agreement, PAs may prescribe insulin glargine. The Louisiana State Board of Medical Examiners oversees PA supervision agreements [6].

Telehealth prescribers practicing across state lines must hold an active Louisiana license or operate under a telemedicine-specific interstate compact. Louisiana participates in the Interstate Medical Licensure Compact for physicians, which allows expedited licensure for out-of-state MDs and DOs seeking to see Louisiana patients [8].

Telehealth Prescribing for Lantus in Louisiana

Louisiana telehealth law, revised under Act 323 (2020) and maintained through subsequent legislative sessions, allows a prescriber to establish a valid patient-prescriber relationship via synchronous audio-visual telehealth without a prior in-person visit [9]. This means a Louisiana resident can complete a video consultation, receive a Lantus prescription electronically, and have it sent directly to a retail or mail-order pharmacy, all within a single afternoon.

The HealthRX clinical team uses the following four-step pathway for new basal insulin starts via telehealth in Louisiana:

1. Lab review (before visit). Upload or order a recent HbA1c (within 90 days), fasting glucose, basic metabolic panel for kidney function, and a lipid panel. Most labs can be ordered same-day through national draw networks such as Quest or LabCorp with results in 24 to 48 hours.
2. Synchronous video visit. A Louisiana-licensed prescriber reviews labs, current medications, injection technique comfort level, and glucose monitoring equipment. Visit duration averages 20 to 30 minutes for a new basal insulin start.
3. Electronic prescription. The prescriber sends a 90-day supply order with three refills to the patient's preferred pharmacy. For patients using insulin pens, the order specifies SoloSTAR cartridges; for vial users, it specifies the 10 mL vial.
4. Pharmacy fulfillment. Local retail pharmacies in Baton Rouge, New Orleans, Shreveport, and Lafayette carry Lantus in stock. Mail-order pharmacies ship refrigerated insulin in insulated packaging, typically arriving within 2, 3 business days.

Asynchronous (store-and-forward) prescribing of Lantus is legally permissible in Louisiana for refills of an established patient's existing regimen, though most telehealth platforms use synchronous video for new starts to meet standard-of-care documentation requirements [9].

What Labs Are Needed Before Starting Lantus?

Prescribers generally require five data points before initiating insulin glargine [3].

HbA1c. This confirms glycemic control status and guides the starting dose. The ADA recommends a target of <7.0% for most non-pregnant adults, with individualization for older patients or those with hypoglycemia unawareness [3].

Fasting plasma glucose. Establishes the baseline from which titration begins. The ORIGIN titration protocol used a target fasting glucose of 95 mg/dL, adjusting the dose by 2 units every 3 days [5].

Basic metabolic panel. Kidney function (eGFR and serum creatinine) affects insulin clearance and hypoglycemia risk. Patients with eGFR <30 mL/min/1.73 m² may need dose reductions and closer monitoring [2].

Body weight. Insulin glargine is dosed at 0.1, 0.2 units/kg/day as a starting dose for type 2 diabetes, or calculated from total daily dose in type 1 patients transitioning from another basal insulin [2].

Current medication list. Thiazolidinediones increase fluid retention with insulin; sulfonylureas increase hypoglycemia risk when combined with basal insulin; SGLT2 inhibitors require attention to diabetic ketoacidosis risk in type 1 patients [3].

A thyroid panel (TSH) is not required before Lantus but is often ordered concurrently in new type 2 diagnoses because hypothyroidism affects glucose metabolism [10].

Louisiana Medicaid and Commercial Insurance Coverage

Louisiana Medicaid (Healthy Louisiana) does not include Lantus on its preferred drug list as of 2025. Managed care organizations operating under Healthy Louisiana, including Aetna Better Health, Healthy Blue, Louisiana Healthcare Connections, and AmeriHealth Caritas, list biosimilar insulin glargine products as preferred alternatives [11].

Covered alternatives on Louisiana Medicaid formularies include:

• Insulin glargine-yfgn (Semglee, Viatris): FDA-approved interchangeable biosimilar to Lantus [12]
• Insulin glargine-aglr (Toujeo U-300, Sanofi): covered on some managed care plans with step therapy
• NPH insulin (Humulin N, Novolin N): covered without prior authorization on most Louisiana Medicaid plans

For commercially insured patients, Lantus requires prior authorization on most plans. The typical prior authorization criteria include a confirmed diagnosis of type 1 or type 2 diabetes, documentation of HbA1c, and in some cases evidence that a formulary-preferred basal insulin was tried and failed or caused adverse effects [13].

Prior Authorization Documentation in Louisiana

Prior authorization (PA) for Lantus in Louisiana commonly requires the following documentation, which the prescribing clinician's office submits to the health plan:

• Diagnosis codes (ICD-10 E10.x for type 1 diabetes; E11.x for type 2 diabetes)
• Most recent HbA1c with date
• Current and previous diabetes medications with start and stop dates
• Clinical rationale for Lantus specifically (for example, formulary alternative caused hypoglycemia, or patient is established and stable on Lantus)
• Prescriber NPI and DEA numbers

Louisiana Blue Cross Blue Shield requires PA for Lantus under its commercial formularies and typically issues decisions within 72 hours of receipt of a complete request [13]. Urgent PA requests citing clinical necessity may be processed within 24 hours.

If a PA is denied, the prescriber may request a peer-to-peer review with the plan's medical director. Approval rates for peer-to-peer reviews for established Lantus patients run higher than initial submission approval rates in most commercial plans, though Louisiana-specific published data on this figure are limited [13].

Transferring an Existing Lantus Prescription to Louisiana

Moving to Louisiana with an existing Lantus prescription is straightforward. Louisiana accepts out-of-state prescriptions for non-controlled prescription drugs, including insulin, provided the prescribing clinician holds a valid license in their home state at the time of writing [14]. A pharmacist at a Louisiana retail chain can transfer the prescription from an out-of-state pharmacy.

For patients whose out-of-state prescriber is not licensed in Louisiana, two options exist. The patient may establish care with a Louisiana-licensed prescriber, bringing records from the prior provider, and receive a new prescription. Alternatively, telehealth platforms that hold Louisiana licensure can issue a bridge prescription while the patient establishes in-person care.

Mail-order pharmacies with national networks, such as CVS Caremark, Express Scripts, and Amazon Pharmacy, can fill an existing Lantus prescription and ship to a Louisiana address without requiring a new prescription if the original remains valid and refills remain [14].

503A Compounding Pharmacies and Insulin Glargine in Louisiana

Louisiana-licensed 503A compounding pharmacies may prepare insulin glargine preparations for individual patients with a valid prescription from a licensed prescriber [15]. This is distinct from commercially manufactured Lantus vials and pens produced by Sanofi under FDA oversight.

Compounded insulin glargine is used in niche clinical scenarios, such as custom concentration formulations for patients with extreme insulin resistance, or when commercial supplies face shortage. The FDA does not recognize compounded insulin as equivalent to FDA-approved insulin products, and the American Diabetes Association states: "Patients should not use compounded insulin as a substitute for FDA-approved insulin products except in extraordinary circumstances" [3].

Louisiana 503A pharmacies cannot ship compounded insulin across state lines to patients in other states without a prescriber-patient relationship already established in Louisiana [15]. Within Louisiana, delivery is permitted.

Cost Assistance Programs for Louisiana Patients

Lantus is expensive without insurance. The list price for a 10 mL vial of Lantus is approximately $316, and a package of five SoloSTAR pens runs approximately $465 [16]. Several assistance pathways exist for Louisiana patients.

Sanofi Insulins Valyou Savings Program. Uninsured or underinsured patients who meet income eligibility criteria (up to 600% of the federal poverty level) pay no more than $99/month for all Sanofi insulins, including Lantus [16]. Enrollment is completed online and takes fewer than 10 minutes.

Sanofi Patient Assistance Program (PAP). Patients below 250% of the federal poverty level and without insurance coverage may receive Lantus at no cost through the PAP. Documentation of income and insurance status is required [16].

Semglee (interchangeable biosimilar). Viatris prices Semglee significantly below Lantus list price, with a cash price near $100/vial at many Louisiana pharmacies. Because Semglee is FDA-designated as interchangeable with Lantus, pharmacists may substitute it without prescriber authorization unless the prescriber writes "dispense as written" [12].

GoodRx and similar discount programs. GoodRx coupons for generic or biosimilar insulin glargine at Louisiana pharmacies frequently bring the cash price below $80/vial. These coupons cannot be combined with insurance.

Louisiana Medicaid's Low-Income Subsidy. Dual-eligible patients (Medicare and Medicaid) may access insulin glargine through Medicare Part D with low-income subsidy, reducing cost-sharing to $0, $3.35/month under the Inflation Reduction Act insulin cap effective January 2023 [17].

Dosing and Administration Basics for Louisiana Patients

Lantus is injected subcutaneously once daily at the same time each day [2]. Injection sites include the abdomen, thigh, upper arm, and buttock; rotating sites within the same region reduces lipohypertrophy. Rotating sites between regions, such as from abdomen in the morning to thigh in the evening, can cause variable absorption and unpredictable glucose responses [18].

Storage before opening: refrigerate at 36°F to 46°F (2°C to 8°C). After first use, the vial or pen may be kept at room temperature (below 86°F/30°C) for up to 28 days [2]. Louisiana's summer heat means patients should avoid leaving insulin in a hot car. An insulated case with a cooling insert is standard advice for any patient who carries insulin in warm climates.

Starting doses for type 2 diabetes are typically 10 units/day or 0.1, 0.2 units/kg/day, whichever is lower, titrated upward by 2 units every 3 days until fasting glucose reaches the individualized target [2, 3]. A systematic review of basal insulin titration algorithms published in Diabetes Care found that self-titration algorithms similar to ORIGIN's protocol achieved target fasting glucose in a median of 8 to 12 weeks [19].

Monitoring After Starting Lantus

Once Lantus is started, ongoing monitoring includes fasting glucose readings (ideally daily during dose titration), HbA1c every 3 months until at goal, then every 6 months, and periodic kidney function panels [3]. Continuous glucose monitors (CGMs) approved by the FDA for insulin-using patients, including the Dexterity G7 and Libre 3, allow pattern management that improves time-in-range without increasing hypoglycemia [20].

Prescribers following the ADA's 2024 Standards of Care should document that patients understand hypoglycemia recognition and treatment: 15 grams of fast-acting carbohydrate (4 glucose tablets, 4 oz juice) at blood glucose <70 mg/dL, repeated in 15 minutes if glucose remains low [3]. Severe hypoglycemia requiring third-party assistance occurred at a rate of 1.0 event per 100 person-years in ORIGIN, a rate patients and caregivers should be aware of before starting therapy [5].